Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 1683 | 0.671 |
09:34 ET | 400 | 0.67634 |
09:36 ET | 528 | 0.685 |
09:39 ET | 700 | 0.69001 |
09:41 ET | 204 | 0.702 |
09:45 ET | 100 | 0.69001 |
09:50 ET | 7249 | 0.69 |
09:57 ET | 600 | 0.6653 |
10:01 ET | 100 | 0.675 |
10:03 ET | 400 | 0.6796 |
10:08 ET | 100 | 0.67 |
10:12 ET | 2700 | 0.6701 |
10:35 ET | 100 | 0.67 |
10:37 ET | 249 | 0.670001 |
10:44 ET | 100 | 0.6793 |
10:50 ET | 1000 | 0.6701 |
10:51 ET | 1349 | 0.6749 |
11:04 ET | 950 | 0.6723 |
11:08 ET | 5000 | 0.674499 |
11:22 ET | 312 | 0.67 |
12:07 ET | 220 | 0.6716 |
12:09 ET | 10072 | 0.66 |
12:23 ET | 175 | 0.6601 |
12:30 ET | 2181 | 0.6717 |
12:45 ET | 100 | 0.662 |
12:52 ET | 200 | 0.67 |
12:57 ET | 133 | 0.662 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.0M | -1.9x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.3M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.6M | 0.5x | +78.05% |
CASI Pharmaceuticals Inc | 72.5M | -2.3x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.0M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.